Jeanne Shen, MD
Pathology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shen’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A148943 · Current
Licensed to practise in California · since 2017 · expires 2027-01-31 · Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas Q4696Physician License · since 2015 · expires 2018-08-31Canc Non-RenewalNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$47,679
Medicare paid this office $47,679 for 429 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Pathology examination of tissue using a microscope, intermediate complexity | 261 | $22,659 | $32 |
| Pathology examination of tissue using a microscope, high complexity | 51 | $7,580 | $131 |
| Pathology examination of tissue using a microscope, moderately high complexity | 48 | $5,029 | $73 |
| Special stained specimen slides to examine tissue, initial procedure | 81 | $3,227 | $31 |
| Special stained specimen slides to examine tissue, each additional procedure | 39 | $3,142 | $25 |
See all 10 services
| Pathology examination of tissue using a microscope, intermediate complexity | 261 | $22,659 | $32 |
| Pathology examination of tissue using a microscope, high complexity | 51 | $7,580 | $131 |
| Pathology examination of tissue using a microscope, moderately high complexity | 48 | $5,029 | $73 |
| Special stained specimen slides to examine tissue, initial procedure | 81 | $3,227 | $31 |
| Special stained specimen slides to examine tissue, each additional procedure | 39 | $3,142 | $25 |
| Pathology examination of specimen during surgery, first tissue block | 18 | $1,729 | $56 |
| Microscopic genetic analysis of tumor, manual | 21 | $1,157 | $37 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 12 | $897 | $75 |
| Pathology examination of tissue using a microscope, moderately low complexity | 72 | $800 | $10 |
| Special stained specimen slides to examine tissue including interpretation and report | 11 | $278 | $11 |
Who their Medicare patients are
429 Original Medicare patients in 2024. Average age 73 · Under 65 7% · 85 and older 8% · Women 51% · Also on Medicaid 25% · Health risk score 1.56. Above the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 72% · Cancer 34% · Diabetes 31% · Coronary heart disease 27% · Chronic kidney disease 25% · Depression 21% · Atrial fibrillation 18% · Heart failure 16% · COPD 14% · Stroke 7% · Dementia 4%.
The office billed $626,314, Medicare allowed $61,211 and paid $47,679; for 1,277 services of 18 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 429 | 1,277 | 73 | 1.56 | $626,314 | $47,679 |
| 2023 | 677 | 2,047 | 72 | 1.40 | $840,637 | $72,657 |
| 2022 | 562 | 1,702 | 72 | 1.30 | $574,683 | $62,762 |
| 2021 | 632 | 1,978 | 72 | 1.34 | $431,177 | $75,632 |
| 2020 | 626 | 1,992 | 71 | 1.58 | $426,748 | $79,634 |
| 2019 | 953 | 2,956 | 71 | 1.36 | $571,515 | $106,123 |
| 2018 | 796 | 2,422 | 71 | 1.44 | $457,431 | $88,276 |
| 2017 | 613 | 1,668 | 69 | 1.55 | $297,163 | $55,084 |
| 2016 | 588 | 1,643 | 67 | 2.10 | $291,278 | $51,152 |
| 2015 | 309 | 877 | 67 | 1.70 | $136,545 | $27,094 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Pathology examination of tissue using a microscope, intermediate complexity | 551 | $45,926 | $33 |
| Special stained specimen slides to examine tissue, initial procedure | 135 | $5,043 | $32 |
| Special stained specimen slides to examine tissue, each additional procedure | 59 | $4,932 | $26 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 57 | $4,568 | $76 |
| Pathology examination of tissue using a microscope, high complexity | 21 | $3,540 | $136 |
| Pathology examination of tissue using a microscope, moderately high complexity | 23 | $2,922 | $77 |
| Pathology examination of specimen during surgery, first tissue block | 19 | $2,042 | $58 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 13 | $1,060 | $82 |
| Microscopic genetic analysis of tumor, manual | 13 | $700 | $39 |
| Special stained specimen slides to identify organisms including interpretation and report | 17 | $467 | $23 |
| Special stained specimen slides to examine tissue including interpretation and report | 21 | $444 | $11 |
| Pathology examination of tissue using a microscope, moderately low complexity | 25 | $273 | $11 |
2022: 11 services
| Pathology examination of tissue using a microscope, intermediate complexity | 452 | $39,070 | $34 |
| Special stained specimen slides to examine tissue, initial procedure | 123 | $4,776 | $32 |
| Pathology examination of tissue using a microscope, high complexity | 32 | $4,634 | $136 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 50 | $3,709 | $74 |
| Pathology examination of tissue using a microscope, moderately high complexity | 25 | $3,013 | $77 |
| Special stained specimen slides to examine tissue, each additional procedure | 42 | $2,997 | $26 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 12 | $969 | $81 |
| Microscopic genetic analysis of tumor, manual | 15 | $701 | $39 |
| Special stained specimen slides to identify organisms including interpretation and report | 21 | $666 | $25 |
| Special stained specimen slides to examine tissue including interpretation and report | 24 | $596 | $11 |
| Pathology examination of tissue using a microscope, moderately low complexity | 33 | $444 | $11 |
2021: 12 services
| Pathology examination of tissue using a microscope, intermediate complexity | 452 | $38,923 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 76 | $6,986 | $27 |
| Pathology examination of tissue using a microscope, high complexity | 45 | $6,275 | $139 |
| Special stained specimen slides to examine tissue, initial procedure | 153 | $5,594 | $33 |
| Pathology examination of tissue using a microscope, moderately high complexity | 45 | $5,153 | $78 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 58 | $4,700 | $77 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 31 | $2,642 | $83 |
| Microscopic genetic analysis of tumor, manual | 32 | $1,642 | $40 |
| Pathology examination of specimen during surgery, first tissue block | 14 | $1,133 | $60 |
| Special stained specimen slides to identify organisms including interpretation and report | 28 | $940 | $25 |
| Pathology examination of tissue using a microscope, moderately low complexity | 50 | $573 | $10 |
| Special stained specimen slides to examine tissue including interpretation and report | 26 | $480 | $11 |
2020: 12 services
| Pathology examination of tissue using a microscope, intermediate complexity | 450 | $40,396 | $35 |
| Pathology examination of tissue using a microscope, moderately high complexity | 65 | $8,233 | $82 |
| Pathology examination of tissue using a microscope, high complexity | 42 | $6,222 | $145 |
| Special stained specimen slides to examine tissue, each additional procedure | 69 | $6,072 | $28 |
| Special stained specimen slides to examine tissue, initial procedure | 147 | $5,805 | $35 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 55 | $4,396 | $80 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 29 | $2,554 | $85 |
| Microscopic genetic analysis of tumor, manual | 34 | $1,950 | $41 |
| Pathology examination of specimen during surgery, first tissue block | 19 | $1,493 | $62 |
| Special stained specimen slides to identify organisms including interpretation and report | 21 | $725 | $26 |
| Special stained specimen slides to examine tissue including interpretation and report | 25 | $574 | $12 |
| Pathology examination of tissue using a microscope, moderately low complexity | 49 | $558 | $11 |
2019: 12 services
| Pathology examination of tissue using a microscope, intermediate complexity | 795 | $67,952 | $34 |
| Special stained specimen slides to examine tissue, initial procedure | 228 | $8,541 | $33 |
| Special stained specimen slides to examine tissue, each additional procedure | 92 | $8,538 | $27 |
| Pathology examination of tissue using a microscope, high complexity | 30 | $4,328 | $140 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 53 | $4,207 | $78 |
| Pathology examination of tissue using a microscope, moderately high complexity | 36 | $4,026 | $79 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 34 | $2,787 | $82 |
| Microscopic genetic analysis of tumor, manual | 25 | $1,400 | $40 |
| Special stained specimen slides to identify organisms including interpretation and report | 44 | $1,328 | $25 |
| Pathology examination of specimen during surgery, first tissue block | 12 | $955 | $60 |
| Special stained specimen slides to examine tissue including interpretation and report | 32 | $677 | $11 |
| Pathology examination of tissue using a microscope, moderately low complexity | 40 | $469 | $11 |
2018: 11 services
| Pathology examination of tissue using a microscope, intermediate complexity | 694 | $59,972 | $35 |
| Special stained specimen slides to examine tissue, initial procedure | 191 | $7,345 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 74 | $5,977 | $27 |
| Pathology examination of tissue using a microscope, moderately high complexity | 38 | $4,639 | $80 |
| Pathology examination of tissue using a microscope, high complexity | 26 | $3,838 | $142 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 21 | $1,659 | $79 |
| Microscopic genetic analysis of tumor, manual | 22 | $1,108 | $43 |
| Pathology examination of specimen during surgery, first tissue block | 15 | $1,033 | $61 |
| Special stained specimen slides to identify organisms including interpretation and report | 33 | $908 | $25 |
| Pathology examination of tissue using a microscope, moderately low complexity | 43 | $486 | $11 |
| Special stained specimen slides to examine tissue including interpretation and report | 18 | $349 | $11 |
2017: 10 services
| Pathology examination of tissue using a microscope, intermediate complexity | 529 | $37,053 | $34 |
| Special stained specimen slides to examine tissue, initial procedure | 135 | $4,879 | $32 |
| Pathology examination of tissue using a microscope, moderately high complexity | 47 | $3,270 | $65 |
| Special stained specimen slides to examine tissue, each additional procedure | 36 | $3,160 | $26 |
| Pathology examination of tissue using a microscope, high complexity | 15 | $1,959 | $131 |
| Special stained specimen slides to examine tissue including interpretation and report | 34 | $876 | $10 |
| Special stained specimen slides to identify organisms including interpretation and report | 20 | $636 | $24 |
| Microscopic genetic analysis of tumor, manual | 11 | $605 | $50 |
| Pathology examination of tissue using a microscope, moderately low complexity | 34 | $326 | $10 |
| Preparation of tissue for examination by removing any calcium present | 14 | $138 | $10 |
2016: 11 services
| Pathology examination of tissue using a microscope, intermediate complexity | 455 | $26,289 | $29 |
| Pathology examination of tissue using a microscope, moderately high complexity | 89 | $7,838 | $69 |
| Pathology examination of tissue using a microscope, high complexity | 34 | $4,300 | $119 |
| Special stained specimen slides to examine tissue, each additional procedure | 55 | $3,900 | $22 |
| Special stained specimen slides to examine tissue, initial procedure | 98 | $3,169 | $29 |
| Pathology examination of specimen during surgery, first tissue block | 16 | $1,298 | $52 |
| Special stained specimen slides to examine tissue including interpretation and report | 38 | $1,056 | $10 |
| Microscopic genetic analysis of tumor, manual | 14 | $946 | $43 |
| Pathology examination of tissue using a microscope, moderately low complexity | 61 | $628 | $9 |
| Special stained specimen slides to identify organisms including interpretation and report | 11 | $382 | $22 |
| Preparation of tissue for examination by removing any calcium present | 13 | $199 | $10 |
2015: 7 services
| Pathology examination of tissue using a microscope, intermediate complexity | 266 | $18,863 | $32 |
| Special stained specimen slides to examine tissue, initial procedure | 61 | $1,969 | $29 |
| Special stained specimen slides to examine tissue, each additional procedure | 28 | $1,608 | $18 |
| Pathology examination of tissue using a microscope, moderately high complexity | 15 | $1,328 | $70 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 13 | $925 | $71 |
| Special stained specimen slides to identify organisms including interpretation and report | 19 | $515 | $22 |
| Pathology examination of tissue using a microscope, moderately low complexity | 15 | $141 | $9 |
Medicaid work
$18,297 in 2024
Medicaid paid $18,297 for 375 billed services this clinician did in 2024, up to 47 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| TISSUE EXAM BY PATHOLOGIST | 262 | $13,544 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 46 | $2,258 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 16 | $1,318 |
| TISSUE EXAM BY PATHOLOGIST | 51 | $1,178 |
| 2024 | 375 | 4 | 47 | $18,297 |
| 2023 | 346 | 2 | 60 | $22,393 |
| 2022 | 297 | 3 | 55 | $23,180 |
| 2021 | 310 | 2 | 50 | $23,830 |
| 2020 | 212 | 3 | 43 | $14,002 |
| 2019 | 567 | 2 | 62 | $33,944 |
| 2018 | 536 | 2 | 73 | $32,972 |
See the largest Medicaid services in earlier years
2023
| TISSUE EXAM BY PATHOLOGIST | 301 | $20,574 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 45 | $1,818 |
2022
| TISSUE EXAM BY PATHOLOGIST | 228 | $20,347 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 56 | $2,533 |
| TISSUE EXAM BY PATHOLOGIST | 13 | $299 |
2021
| TISSUE EXAM BY PATHOLOGIST | 262 | $21,839 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 48 | $1,991 |
2020
| TISSUE EXAM BY PATHOLOGIST | 174 | $13,074 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 24 | $612 |
| TISSUE EXAM BY PATHOLOGIST | 14 | $316 |
2019
| TISSUE EXAM BY PATHOLOGIST | 514 | $32,188 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 53 | $1,755 |
2018
| TISSUE EXAM BY PATHOLOGIST | 432 | $28,832 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 104 | $4,140 |
Money from drug and device companies
$3,719 in 2025
A payment is not proof that care is biased.
| Roche Molecular Systems | None | $3,719 | 8 payments
|
See all 8 published payments
| Roche Molecular Systems | Paid to speak or teach · 2025-06-11 | None | $1,500 |
| Roche Molecular Systems | Travel · 2025-04-03 | None | $64 |
| Roche Molecular Systems | Travel · 2025-04-02 | None | $279 |
| Roche Molecular Systems | Travel · 2025-04-01 | None | $419 |
| Roche Molecular Systems | Travel · 2025-04-01 | None | $279 |
| Roche Molecular Systems | Education · 2025-04-01 | None | $850 |
| Roche Molecular Systems | Travel · 2025-04-01 | None | $49 |
| Roche Molecular Systems | Travel · 2025-03-31 | None | $279 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1821314493
- Licence
- CA A148943, MA 261599, TX Q4696California A148943: Current · expires 2027-01-31Texas Q4696: Canc Non-Renewal
- Trained
- Washington University School of Medicine, 2010
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2010-04-08
- NPI last updated
- 2024-03-13
- NPI record certified
- 2024-03-13
This is when the NPI record was last certified, not a medical board exam.